| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Cell Source, Inc. | Director | Common Stock | 114,927 | $86,195 | $0.7500 | 30 Jun 2021 | Direct |
| Kintara Therapeutics, Inc. | Chief Scientific Officer | Options (Right to Buy) | 10,175 | 30 Aug 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| HURA | Kintara Therapeutics, Inc. | 30 Aug 2023 | 1 | $0 | 4 | Chief Scientific Officer | 01 Sep 2023, 18:00 |
| HURA | Kintara Therapeutics, Inc. | 05 Jan 2023 | 1 | $0 | 4 | Chief Scientific Officer | 06 Jan 2023, 18:26 |
| HURA | Kintara Therapeutics, Inc. | 01 Aug 2022 | 2 | $0 | 4 | Chief Scientific Officer | 03 Aug 2022, 16:30 |
| CLCS | Cell Source, Inc. | 30 Jun 2021 | 1 | +$2,232 | 4 | Director | 07 Jul 2021, 12:53 |
| CLCS | Cell Source, Inc. | 13 Feb 2019 | 5 | +$58,966 | 4 | Director | 10 Jun 2021, 13:40 |